Epidemiological characteristics of breakthrough mumps infection cases from 2019 to 2023 in Chongqing, China.

IF 4.1 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-11-13 DOI:10.1080/21645515.2024.2426273

Yang Liu, Xiaoya Cai, Deming Yang, Yu Xiang, Qing Wang, Ning Yao, Yuanyuan Zhang, Jiawei Xu

{"title":"Epidemiological characteristics of breakthrough mumps infection cases from 2019 to 2023 in Chongqing, China.","authors":"Yang Liu, Xiaoya Cai, Deming Yang, Yu Xiang, Qing Wang, Ning Yao, Yuanyuan Zhang, Jiawei Xu","doi":"10.1080/21645515.2024.2426273","DOIUrl":null,"url":null,"abstract":"The high coverage of mumps-containing vaccine (MuCV) has effectively controlled the mumps incidence, while the prevention and control of breakthrough cases has become a prominent problem. To analyze the epidemiology of mumps breakthrough cases in Chongqing from 2019 to 2023, and provide scientific evidence for the prevention and control of mumps. The data of clinical and laboratory-confirmed mumps cases in Chongqing from 2019 to 2023 were exported from the China Information System for Disease Control and Prevention. The immunization history was screened and matched from the Chongqing Immunization Program Information System. Least-Significant Difference (LSD) and T-test were used for data analysis. There were 12,566 breakthrough cases in Chongqing, accounting for 61.09% of the total mumps cases reported. The most breakthrough infection occurred in the 3-9 years age group. In 2019 and 2020, the mean age of breakthrough cases with two doses was older than that with one dose (p < .05). In 2022 and 2023, the age was younger than that with one dose (p < .05). The breakthrough intervals for one dose and two doses were (4.87 ± 2.57) and (2.01 ± 1.79) years, respectively. The proportion of breakthrough mumps cases continues to increase in highly vaccinated populations in Chongqing. It is necessary to carry out research on a supplementary dose of MuCV vaccination strategy, and enhance the monitoring of mumps outbreaks in key populations such as children in kindergartens and primary schools.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2426273"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2426273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The high coverage of mumps-containing vaccine (MuCV) has effectively controlled the mumps incidence, while the prevention and control of breakthrough cases has become a prominent problem. To analyze the epidemiology of mumps breakthrough cases in Chongqing from 2019 to 2023, and provide scientific evidence for the prevention and control of mumps. The data of clinical and laboratory-confirmed mumps cases in Chongqing from 2019 to 2023 were exported from the China Information System for Disease Control and Prevention. The immunization history was screened and matched from the Chongqing Immunization Program Information System. Least-Significant Difference (LSD) and T-test were used for data analysis. There were 12,566 breakthrough cases in Chongqing, accounting for 61.09% of the total mumps cases reported. The most breakthrough infection occurred in the 3-9 years age group. In 2019 and 2020, the mean age of breakthrough cases with two doses was older than that with one dose (p < .05). In 2022 and 2023, the age was younger than that with one dose (p < .05). The breakthrough intervals for one dose and two doses were (4.87 ± 2.57) and (2.01 ± 1.79) years, respectively. The proportion of breakthrough mumps cases continues to increase in highly vaccinated populations in Chongqing. It is necessary to carry out research on a supplementary dose of MuCV vaccination strategy, and enhance the monitoring of mumps outbreaks in key populations such as children in kindergartens and primary schools.

查看原文本刊更多论文

2019-2023年中国重庆市突破性流行性腮腺炎感染病例的流行病学特征。

流行性腮腺炎疫苗（MuCV）的高覆盖率有效控制了流行性腮腺炎的发病率，而突破性病例的防控成为突出问题。为分析2019年至2023年重庆市流行性腮腺炎突破性病例的流行病学情况，为流行性腮腺炎的防控提供科学依据。从中国疾病预防控制信息系统导出重庆市2019年至2023年流行性腮腺炎临床和实验室确诊病例数据。免疫接种史从重庆市免疫规划信息系统中筛选并匹配。数据分析采用最小显著性差异（LSD）和T检验。重庆市共有 12,566 例突破性感染病例，占腮腺炎报告病例总数的 61.09%。突破性感染多发生在3-9岁年龄组。在 2019 年和 2020 年，接种两剂的突破性感染病例的平均年龄比接种一剂的病例大（P P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

CiteScore

7.90

自引率

8.30%

发文量

489

审稿时长

3-6 weeks

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.